索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张磊,李伟,段宗刚,等.P2Y12，受体抑制剂单药抗血小板策略在不同人群中的研究进展[J].国际心血管病杂志,2022,01:17-20.
点击复制

P2Y12，受体抑制剂单药抗血小板策略在不同人群中的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年01期
页码:
17-20
栏目:
综述
出版日期:
2022-02-10

文章信息/Info

Title:
-
作者:
张磊; 李伟; 段宗刚; 熊信林; 王清腾; 邓媛
作者单位：550000 贵州医科大学研究生院
Author(s):
-
关键词:
P2Y12 受体抑制剂; 单药抗血小板; 经皮冠状动脉介入治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.01.005
文献标识码:
-
摘要:
在新型药物洗脱支架时期，各种介入治疗手段的进步使得冠状动脉介入术后的 抗血小板降级策略兴起。多项研究表明缩短双抗时程安全有效，但后续持续使用阿司匹林有 较大的出血风险，新型P2Y12 受体抑制剂早期单药抗血小板策略可以较好的平衡出血与缺 血风险，并具有良好的疗效及安全性，但尚未广泛应用于临床。
Abstract:
-

参考文献/References

[1] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/ EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2):87-165.
[2] Verdoia M, Kedhi E, Suryapranata H, et al. Benefits of shortterm or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drugeluting stents: a meta-analysis of 9 randomized trials[J]. J Thromb Thrombolysis, 2020, 50(2):337-354.
[3] Verdoia M, Khedi E, Suryapranata H, et al. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials[J]. Rev Esp Cardiol (Engl Ed), 2021, 74(2):140-148.
[4] Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial[J]. JAMA, 2019, 321(24):2428-2437.
[5] Takahashi K, Serruys PW, Chichareon P, et al. Efficacy and safety of ticagrelor monotherapy in patients undergoing multivessel PCI[J]. J Am Coll Cardiol, 2019, 74(16):2015- 2027.
[6] Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial[J]. JAMA, 2019, 321(24):2414-2427.
[7] Miyazaki Y, Suwannasom P, Sotomi Y, et al. Single or dual antiplatelet therapy after PCI[J]. Nat Rev Cardiol, 2017, 14(5):294-303.
[8] Claassens D, Vos G, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI[J]. N Engl J Med, 2019, 381(17):1621-1631.
[9] Pereira NL, Farkouh ME, So D, et al. Effect of genotypeguided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial[J]. JAMA, 2020, 324(8):761-771.
[10] Greco A, Capodanno D. Long-term monotherapy with ticagrelor after coronary stenting: the GLOBAL LEADERS study[J]. Eur Heart J Suppl, 2020, 22(Suppl E):E46-E49.
[11] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11):1045-1057.
[12] Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial[J]. Lancet, 2018, 392(10151):940- 949.
[13] Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting[J]. J Am Coll Cardiol, 2019, 74(18):2223-2234.
[14] Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI[J]. N Engl J Med, 2019, 381(21):2032-2042.
[15] Tomaniak M, Chichareon P ,Onuma Y, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial[J]. JAMA Cardiol, 2019, 4(11):1092-1101.
[16] Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS[J]. Eur Heart J, 2020, 41(37):3533-3545.
[17] Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial[J]. JAMA, 2020, 323(23):2407-2416.
[18] Lee SJ, Cho JY, Kim BK, et al. Ticagrelor monotherapy versus ticagrelor With aspirin in patients with ST-segment elevation myocardial infarction[J]. JACC Cardiovasc Interv, 2021, 14(4):431-440.
[19] Chichareon P, Modolo R, Kogame N, et al. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study[J]. Atherosclerosis, 2020, 295:45-53.
[20] Angiolillo DJ, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention[J]. J Am Coll Cardiol, 2020, 75(19):2403-2413.
[21] Yun KH, Cho JY, Lee SY, et al. Ischemic and bleeding events of ticagrelor monotherapy in Korean patients with and without diabetes mellitus: insights from the TICO trial[J]. Front Pharmacol, 2020, 11:620-906.
[22] Wang Q, Yang K, Bundhun PK. Discontinuing aspirin after short term use versus continuous use with a P2Y12 inhibitor for the treatment of patients with type 2 diabetes mellitus following percutaneous coronary intervention: a metaanalysis[ J]. Diabetes Ther, 2020, 11(10):2299-2311.
[23] Serruys PW, Takahashi K, Chichareon P, et al. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial[J]. Eur Heart J, 2019, 40(31):2595-2604.
[24] Kogame N, Chichareon P, De Wilder K, et al. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial[J]. Catheter Cardiovasc Interv, 2020, 96(1):100-111.
[25] Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI[J]. J Am Coll Cardiol, 2020, 75(19):2414-2424.
[26] Benetou DR, Andreou I, Varlamos C, et al. Tailoring dual antiplatelet therapy for the complex PCI patient: current status and perspectives[J]. Cardiovasc Drugs Ther, 2020, 34(5):697- 706.
[27] Tomaniak M, Chichareon P, Modolo R, et al. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial[J]. EuroIntervention, 2020, 15(18):e1605-e1614.
[28] Roxana M. Ticagrelor with or without aspirin in Chinese patients undergoing PCI[EB/OL].
[2020-11-30].https://www. pcronline. com/Cases resources images/Resources/Course videos slides/2020/Hot line on PCI high bleeding risk and DAPT part 2/.
[29] Zhou X, Li Y, Yang Q. Antiplatelet therapy after percutaneous coronary intervention in patients with COVID-19: implications from clinical features to pathologic findings[J]. Circulation, 2020, 141(22):1736-1738.
[30] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2020, 42(14):1289-1367.
[31] Natsuaki M, Morimoto T, Watanabe H, et al. Clopidogrel monotherapy vs. Aspirin monotherapy following short-term dual antiplatelet therapy in patients receiving everolimuseluting coronary stent implantation[J]. Circ J, 2020, 84(9):1483-1492.
[32] Kogame N, Guimar?es PO, Modolo R, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study[J]. JACC Cardiovasc Interv, 2020, 13(19):2251-2262.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81960047）；贵州省科技厅支撑项 目（黔科合支撑[2019]2800 号）
通信作者：李伟，Email:liwei249188@sina.com
更新日期/Last Update: 2022-02-10